Genotoxic Impurities: A Quantitative Approach

High-Performance Liquid Chromatography Methods for Determining the Purity of Drugs with Weak UV Chromophores - A Review

High-performance liquid chromatography (HPLC) is one of the most useful techniques for the separation and determination of new drugs with a complex nature. The selection of an HPLC detector depends on the chemical nature of molecules, potential impurities, matrix of the sample, sensitivity, availability, and/or cost of the detector. HPLC methods with UV/Vis detectors are the most used and simple analytical procedures in pharmaceutical applications, but it is limited to compounds that possess a chromophore. Hence, this review provides an overview on the development of analytical methods for compounds with weak chromophores. The review described selected papers about HPLC based methods in the PubMed, Scopus, Semantic Scholar and ScienceDirect databases, basically between 2006 and 2023. Of the analytical studies, the HPLC methods with UV-Vis, FLD, CAD, ELSD, RID, ECD, CLND and MS detection were found. This study is a comparison of different types of detection that are described in scientific literature and are routinely used for compounds with weak chromophores. It is expected that this review will be helpful for scientists in the analytical development fields to improve research related to the drug candidates and to ensure its quality according to regulatory levels.

Highly sensitive LC-MS method for stereochemical quality control of a pharmaceutical drug substance intermediate

Stereochemical quality control for pharmaceutical drug substance intermediates is a daunting task, especially considering the need to separate multiple stereoisomers simultaneously with low ppm level sensitivity. To address these challenges, we have successfully implemented chiral column screening, and developed an ultrasensitive liquid chromatography-mass spectrometry (LC-MS) method to separate four stereoisomers including the API intermediate, its enantiomer, and two other diastereomers. Parameters such as mobile phase additives, MS fragmentor, and column temperature were optimized to achieve the desired selectivity and sensitivity. The method enabled stereoisomer detection with high sensitivity (2 ppm LOD and 5 ppm LOQ), good linearity, and desired spike recovery, and it has been successfully applied for stereoisomer quantitation in multiple large-scale batches and demonstrated chiral quality control of the drug substance intermediate.

Overall impact of the regulatory requirements for genotoxic impurities on the drug development process

In the last decade a considerable effort has been made both by the regulators and the pharmaceutical industry to assess genotoxic impurities (GTI) in pharmaceutical products. Though the control of impurities in drug substances and products is a well established and consolidated procedure, its extension to GTI has given rise to a number of problems, both in terms of setting the limits and detecting these impurities in pharmaceutical products. Several papers have dealt with this issue, discussing available regulations, providing strategies to evaluate the genotoxic potential of chemical substances, and trying to address the analytical challenge of detecting GTI at trace levels. In this review we would like to discuss the available regulations, the toxicological background for establishing limits, as well as the analytical approaches used for GTI assessment. The final aim is that of providing a complete overview of the topic with updated available information, to address the overall GTI issue during the development of new drug substances.